WGOG-PAN 006/ICSBR-2: Randomized Trial Data for Pancreatic Cancer Treatment

A Phase III clinical trial protocol comparing a novel radio-immuno-chemotherapy regimen to standard chemotherapy for recurrent or metastatic pancreatic ductal adenocarcinoma. The study, authored by Xin Wang, plans to enroll 198 patients and measures outcomes including overall survival and progression-free survival. The dataset was last updated on 2026-05-13.

Use Cases

• Compare overall survival rates based on the described treatment regimens.
• Analyze progression-free survival outcomes for patients receiving the experimental combination therapy.
• Evaluate safety profiles and adverse events based on NCI-CTCAE v5.0 assessments.
• Investigate immune spatial interactions using the described cyclic multiplex tissue staining assays.

Strengths

• The protocol is for a Phase III randomized trial, which is a high level of clinical evidence.
• The study has a defined primary endpoint (Overall Survival) and multiple secondary endpoints.
• The dataset is licensed under CC-BY-4.0, allowing for open reuse.

Limitations

• The dataset is a 15.3 KB DOCX file, indicating a very small scale, likely containing only the trial protocol document.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for quantitative analysis.

Provenance

Source

Xin Wang via figshare

Collection Method

Prospective, randomized, open-label, multicenter Phase III clinical trial.

Freshness

Last updated 2026-05-13 04:47:39; freshness should be verified.

Geography

Multicenter; specific locations not stated.